New England Surgical Society (NESS)
Search NESS
  Annual Meeting
  Annual Resident and Fellow Research Day
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Journal of the American College of Surgeons
  Contact NESS

2010 Annual Meeting Abstracts

Back to Program

T-cell immune responses after cryotherapy of breast cancer
Richard J Barth, Jr.1, *Dawn Fischer1, *Jacqueline Channon1, Wendy Wells1, *Gary Levine2, *Steve Poplack1
1Dartmouth, Lebanon, NH;2Hoag Memorial Presbyterian Hospital, Newport Beach, CA

Objective: Murine studies have demonstrated that cryotherapy can induce anti-tumor immune responses. Our objective was to determine whether cryotherapy of human breast cancer can induce an anti-tumor T-cell immune response.
Design: Prospective study.
Setting: Two academic tertiary care medical centers.
Patients: Twenty patients with infiltrating ductal carcinomas less than 1.5 cm in diameter.
Interventions: Under ultrasound guidance and local anesthesia the patient’s tumors underwent cryoablation with 2 freeze-thaw cycles. Blood samples were obtained prior to and 1 week after cryoablation. Tumors were resected 4 weeks after cryoablation.
Main outcome measures: Pentamer analysis for T-cells specific for breast cancer associated peptides Her-2 neu, CEA, Muc-1. Interferon γ ELISPOT analysis for these peptides plus NYBR-1, folate receptor α and MCF-7 breast cancer cell line lysate.
Results: Pathologic evaluation of all resected specimens showed no evidence of viable cancer cells in the cryoablation zone. T-cells specific for control peptides from the common viruses CMV and influenza were detected in patients with both pentamer and ELISPOT assays. Tumor peptide reactive T-cells were detected in patients prior to and after cryoablation. There was no increase in mean tumor peptide specific T-cell frequencies by pentamer analysis and there was no increase in mean interferon γ secreting, tumor peptide specific T-cells by ELISPOT analysis after cryoablation.
Conclusions: Cryoablation of small breast cancers in patients resulted in histologic evidence of tumor destruction, but did not induce a detectable anti-tumor T-cell immune response.

Back to Program


Copyright © 2020 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.